Study of PLX-61639 for advanced SMARCA4-mutant solid tumors
Part of Cancer, Digestive system, Lungs & breathing clinical trials.
This trial is testing a new drug called PLX-61639 for people with advanced solid tumors that have a specific SMARCA4 gene change. The drug aims to stop cancer growth by targeting the cells that lack this gene.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your tumor must have a certain gene change called a SMARCA4 loss-of-function mutation.
- You must have tried other standard treatments and they didn't work, or you couldn't take them.
- You need to be in fairly good overall health (able to do daily activities with little or no help).
- Your cancer must be measurable on scans (such as CT or MRI).
- You must not have a history of serious heart problems or uncontrolled high blood pressure.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, LY4050784, for people with advanced solid tumors that have a specific change in a gene called SMARCA4 (BRG1). The study aims to see if the drug is safe and effective. It may be an option for those who have tried other treatments or have no standard options left.
This trial tests a new drug (GS-5319) for adults with advanced solid tumors that have a specific genetic feature called MTAP deficiency. The drug may be given alone or with another treatment, and the goal is to see if it can shrink tumors or slow their growth.
This trial tests a new medicine, PF-08046876, for people with advanced cancers of the bladder, lung, head and neck, esophagus, or pancreas. It aims to see if the drug is safe and works against these cancers.
This trial tests a new immunotherapy drug (QL1706) combined with standard chemotherapy for people with advanced lung cancer that has a specific genetic change (loss of the SMARCA4 gene). The goal is to see if this combination works better than chemo alone.
This trial tests a new drug (FHD-286) for a specific type of advanced lung cancer called small cell lung cancer (SCLC) that has grown back after prior chemotherapy. The drug targets cancer cells that have a specific protein marker called POU2F3.
This trial tests combining anlotinib (a targeted drug that blocks tumor blood vessels) with standard chemotherapy for a rare type of advanced lung cancer that lacks the SMARCA4 gene. The goal is to see if this combination helps people who haven't had treatment before.
Hear when a new Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.